NCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
Clinical Trials
5 trialsNCT02323659 2022-01-13
Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas
Polish Lymphoma Research Group
Phase 4 Terminated
NCT03552549 2019-07-24
SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT01409174 2017-05-31
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00613509 2016-04-14
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Sanofi
Phase 2 Terminated